| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
p53 protein expression in tumor-stromal fibroblasts was closely associated with the number of nodal metastasis and the outcome of invasive ductal carcinoma(IDC) patients of the breast who received and who did not receive neoadjuvant therapy. Furthermore, the Allred score risk classification based on the combined assessment of p53 expression in tumor-stromal fibroblasts forming and not forming FFs is a very useful outcome predictor among patients with IDC who did not receive neoadjuvant therapy.
The grading system for lymph vessel tumor emboli was an excellent histological outcome predictive grading system for IDC patients who received and who did not receive neoadjuvant therapy.
The presence of atypical tumor-stromal fibroblasts, especially in fibrotic foci, was significantly associated with tumor recurrence and tumor-related death of patients with IDC of the breast who received and who did not receive neoadjuvant therapy.
The presence of six or more mitotic figures in a lymph node tumor
… More
significantly increased the hazard ratios for tumor recurrence and tumor-related death among IDC patients as a whole, those with nodal metastases, and those with a histologic grade of 2 or 3.
Type 4 IDC was significant outcome predictors for lymph node-negative and-positive, UICC pTNM stages II and III, luminal A-subtype, luminal B-subtype, and equivocal HER2 subtype IDC patients. Lymph vessel tumor embolus grades 2 and 3 were significant outcome predictors for lymph node-positive, UICC pTNM stages II and III, luminal A-subtype and triple negative IDC patients. A more than five mitotic figures in metastatic carcinoma to the lymph nodes was a significant outcome predictor for lymph node-positive, UICC pTNM stage II and luminal A-subtype IDC patients. A fibrotic focus diameter> 8 mm was a significant outcome predictor for UICC pTNM stages I and III IDC patients.
The modified PVN classification clearly exhibited a superior significant power, compared with UICC pTNM classification and the reclassified Nottingham Prognostic Index, for the accurate prediction of tumor recurrence and tumor-related death among patients with IDC in a manner that was independent of the nodal status, the hormone receptor status and adjuvant therapy status. Less
|
